After their primary breast cancer therapy, many women go on to take the aromatase inhibitor letrozole (Femara) for 5 years to reduce the risk of recurrence. In a large clinical trial, researchers found that an additional 5 years of treatment with letrozole continues reduce the risk. On the other hand, the extra therapy had no effect on overall survival. The results will be presented at the American Society of Clinical Oncology annual meeting in Chicago, and were simultaneously published in the New England Journal of Medicine. The study is discussed in this video by , of Harbor-UCLA Medical Center in Torrance, Calif.; , of the Washington University School of Medicine in St. Louis; and of the University of Alabama School of Medicine in Birmingham.